According to the data, in Italy, almost ** percent of patients with a diagnosis of depression used antidepressants in 2021. In the north of the country, **** percent of patients diagnosed with depression used antidepressants. This statistic shows the prevalence of antidepressant use in Italy in 2021, by geographical area.

According to the data, in Italy, almost ** percent of patients with a diagnosis of depression used antidepressants in 2021. Women diagnosed with depression had a higher prevalence of antidepressant use compared to men. This statistic shows the prevalence of antidepressant consumption in Italy in 2021, by gender.

The pharmaceutical consumption of antidepressants in the United Kingdom increased by 6.5 defined daily doses per 1,000 inhabitants per day (+4.94 percent) in 2021 in comparison to the previous year. Therefore, the consumption in the United Kingdom reached a peak in 2021 with 138.2 defined daily doses per 1,000 inhabitants per day. Notably, the consumption in this industry continuously increased over the last years.Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

Across the selected European countries, Germany had the highest expenditure on antidepressant drugs (AD) in 2021, with an expenditure of 845 million U.S. dollars. Spain and Italy followed, with 722 and 481 million U.S. dollars spent on antidepressants, respectively. This statistics depicts the total expenditure on AD in selected European countries in 2021.

This statistic shows the number of users of antidepressants in Norway from 2008 to 2021. The lowest number of users was in 2008, with 60.49 users per thousand inhabitants. Later, the number was increasinguntil 2021, when it peaked at nearly 69 users per thousand inhabitants.

The pharmaceutical consumption of antidepressants in Czechia increased by 3.7 defined daily doses per 1,000 inhabitants per day (+5.63 percent) since the previous year. Therefore, the consumption in Czechia reached a peak in 2021 with 69.4 defined daily doses per 1,000 inhabitants per day. Notably, the consumption in this industry continuously increased over the last years.Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

IntroductionHypnotic polypharmacy and its long-term prescriptions constitute the inappropriate use of hypnotics. However, the relationship between hypnotic polypharmacy and prolonged prescriptions remains unclear. This study aimed to elucidate the association between hypnotic polypharmacy and the duration of hypnotic prescriptions.MethodsThis retrospective, cross-sectional study utilized a large dataset from the Japan Medical Data Center. The study population included adults who had been prescribed hypnotics between April 2020 and March 2021, with a focus on those receiving hypnotics in March 2021. Hypnotic polypharmacy was defined as the concurrent prescription of two or more hypnotics in March 2021. The duration of hypnotic prescriptions was measured by calculating the number of months between April 2019 and March 2021 during which hypnotics were prescribed. A binary logistic regression analysis was conducted to assess the relationship between hypnotic polypharmacy and long-term hypnotic prescriptions, adjusting for relevant covariates.ResultsWe included 112,256 patients (mean age: 49.5 years, females: 47.1%). Among them, 67.9% received hypnotic monotherapy, and 32.1% received hypnotic polypharmacy. Compared with adults who were prescribed hypnotics for 1 month, the association with polypharmacy was stronger in those who were prescribed hypnotics for ≥4 months as the duration of the prescription increased (adjusted odds ratio [aOR]: 1.15, 95% confidence interval [CI]: 1.04–1.27, p=0.006 for 4–6 months; aOR 1.35, 95% CI 1.23–1.49, p

The pharmaceutical consumption of antidepressants in Germany increased by 1.8 defined daily doses per 1,000 inhabitants per day (+2.89 percent) since the previous year. With 64 defined daily doses per 1,000 inhabitants per day, the consumption thereby reached its highest value in the observed period. Notably, the consumption in this industry continuously increased over the last years.Find more statistics on other topics about Germany with key insights such as value of pharmaceutical sales and consumption of antihypertensives.

Here is the README file with description and Supporting Data for the Thesis "Characterization of the Chinese Medicine Banxia-Houpo Decoction for the Development of a Six-Compound Combination and Synthetic Derivatives as Potential Antidepressant Therapy" by Yilu Sun (3030082882, School of Chinese Medicine, Li Ka Shing Faculty of Medicine).Project Description:This project aimed to: 1) determine the antidepressant effects of a Traditional Chinese Formula BHD and the derived bioactive compounds combo against depression in mice; 2) develop a novel remedy for depression; 3) discover new mechanisms.We performed LC-MS profiling and network pharmacology analysis in this project to identify bioactive compounds and depression-associated genes. CORT-lesioned mice and highly differentiated (HD) PC12 cells were used to test the efficacy.To develop novel drugs, the compound was synthesized and characterized using UPLC-UV/MS and NMR. The safety, antidepressant and anti-inflammatory effects were tested in a mouse model.To further explore the mechanism of depression, we developed a transgenic mouse model. A novel pathway was proposed by RNA sequencing and verified by qRT-PCR and Western blot.Project Start date: 09-01-2021 Project End date: 07-11-2025Sample Size: A total of 150 mice were used (6 animals for each group). No human was involved.

The pharmaceutical consumption of antidepressants in Slovakia increased by 1.8 defined daily doses per 1,000 inhabitants per day (+4.2 percent) since the previous year. With 44.7 defined daily doses per 1,000 inhabitants per day, the consumption thereby reached its highest value in the observed period. Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Netherlands.

Serotonin reuptake inhibitor (SRI) antidepressants are implicated in increasing the risk of bleeding among users; however, the comparative increase in bleeding risk with concurrent antithrombotic therapy (anticoagulant or antiplatelet) remains unclear. As such, we performed a systematic review and meta-analysis of all available evidence to evaluate the effects of SRI and the risk of bleeding complications among patients receiving antithrombotic therapy. We searched Medline, Embase, PubMed, PsycINFO, Cochrane Library, Web of Science, Scopus, CINAHL, and grey literature (Google Scholar and preprint reports) up to 26 November, 2020, with no language restrictions (updated on 31 July 2021). The primary outcome of interest was major bleeding. Secondary outcomes included intracranial haemorrhage, gastrointestinal bleeding, and any bleeding events. We used a random-effects model meta-analysis to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). We did not identify any randomised studies but found 32 non-randomized studies (cohort or case–control) with 1,848,285 patients that fulfilled the study selection criteria and were included in the meta-analysis. Among individuals receiving anticoagulants (13 studies), SRI users experienced a statistically higher risk of major bleeding compared to non-SRI users: pooled OR was 1.39 (95% CI, 1.23–1.58; p 

In 2021, the pharmaceutical consumption of antidepressants in the Netherlands remained nearly unchanged at around 48.5 defined daily doses per 1,000 inhabitants per day. Nevertheless, 2021 still represents a peak in the consumption in this industry in the Netherlands. Find more key insights for the pharmaceutical consumption in countries like Belgium, Luxembourg, and Estonia.

In 2021, the defined daily dosage for antidepressants in Austria averaged at around 63.5 per 1,000 inhabitants. In general, antidepressant DDDs are slowly but steadily increasing in Austria. This statistic displays the daily consumption of antidepressants in Austria from 2010 to 2021.

Globally, antidepressant usage has been on the rise. As of 2023, among select Organization for Economic Cooperation and Development (OECD) countries, Iceland, Portugal, and the UK were the biggest consumers of antidepressants. At that time, people in Iceland consumed antidepressants at a rate of about *** defined daily doses (DDD) per 1,000 people. Mental health globally Mental health disorders affect a significant proportion of the population, though addressing and understanding the prevalence of mental health is difficult due to regional differences in diagnostic criteria and understandings of mental health. Despite barriers to gathering data on mental health, there have been some global quantitative studies to help better understand certain conditions. It is suggested that mental health is among the top three health concerns among adults worldwide. Estimates propose that about ** percent of the overall population suffers from some mental health or substance use disorder. Depression and anxiety A global survey showed that the largest numbers of people with anxiety resided in locations in South-East Asia and the Americas. However, the highest distribution of cases of depression globally is among populations in South-East Asia and the Western Pacific. Both depression and anxiety disproportionately impact women in all regions of the world.

[179+ Pages Report] The global Pain Management Therapeutics market Size was witnessed USD 72,065.3 Million in 2020 and with growth at a CAGR of 4.8% is expected to reach USD 90,501.8 Million by 2026.

The number of people suffering from depression in Poland has maintained an upward trend over the observed period. The number of patients under age ** buying antidepressants increased by nearly *** percent in the observed period, reaching **** thousand in 2021.

Based on pharmacy claims of those who filled at least one prescription for mental health medication in 2019, antidepressant use is most prevalent in West Virginia, Kentucky, Vermont, and New Hampshire. This statistic shows the percentage of patients (excluding those on government-sponsored benefits) who filled a prescription for antidepressants in the U.S. in 2019, by state.

In the 2021 financial year in New Zealand, there were over *********** initial dispensings of antidepressants in the country, of which almost *********** were dispensed to adults aged between 20 and 64 years of age.

The pharmaceutical consumption of antidepressants in Belgium increased by 2.4 defined daily doses per 1,000 inhabitants per day (+2.86 percent) in 2021. Therefore, the consumption in Belgium reached a peak in 2021 with 86.2 defined daily doses per 1,000 inhabitants per day. Find more key insights for the pharmaceutical consumption in countries like Luxembourg, Netherlands, and Estonia.

In 2022, there were an estimated ***** overdose deaths in the U.S. from antidepressants, an increase from ***** deaths in 2000. This statistic presents the number of overdose deaths from antidepressants in the U.S. from 1999 to 2022.